Bluebird Bio | BLUE - Actif À Court Terme



Actif À Court Terme Changement Date
Agios Pharmaceuticals USD 752.1M 34.43M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.36B 598M 2026-09
Arrowhead Research USD 1.67B 168.34M 2026-06
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Incyte USD 5.52B 505.2M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
Moderna USD 7.34B 1.53B 2026-09
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Novartis USD 28.75B 1.4B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
PTC Therapeutics USD 2.54B 79.58M 2026-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.27B 49.06M 2026-09
Tectonic Therapeutic USD 231.1M 8.79M 2026-06
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09